LONDON (Reuters) - GlaxoSmithKline has started testing its pandemic H1N1 swine flu vaccine in humans, and expects to start giving the results to government agencies next month, the drugmaker said on Friday.
Britain’s Chief Medical Officer Liam Donaldson said on Thursday that vaccination would start for at-risk people in October, and Glaxo is expected to be the country’s main supplier.
The company said that the first tests were being done on 128 healthy adults at a site in Germany, and in the next few weeks it would also start testing children and elderly people.
It plans to conduct 16 different trials of the vaccine and to test 9,000 people in total across Europe, Canada and the United States.
Reporting by Ben Deighton